Learn about UCSF’s response to the coronavirus outbreak, important updates on campus safety precautions, and the latest policies and guidance on our COVID-19 resource website. You can also access information from the CDC. Learn more
UCSF scientists were able to arrest, and even reverse, tissue scarring of the liver, kidneys and lungs in mice. The scarring, also known as fibrosis, is a major factor in nearly half of all deaths in developed countries.
A UCSF opthamologist and bioengineer are collaborating to develop a tiny, flexible, implantable film that's able to deliver conventional medicines and also complex antibody-based drugs to treat eye diseases.
The way cells divide to form new cells – to support growth, to repair damaged tissues, or simply to maintain our healthy adult functioning – is controlled in previously unsuspected ways, UCSF researchers have discovered.
A new link between meal times and daily changes in the immune system has been identified by UCSF researchers, and has led them to question assumptions about the roles of specific immune cells in infection and allergy.
An antihistamine discovered in the 1950s to treat itching may also prevent seizures in an intractable form of childhood epilepsy, according to researchers at UC San Francisco who tested it in zebrafish bred to mimic the disease.
Researchers have probed deep into the cell’s genome to begin learning the “grammar” that helps determine whether or not a gene gets switched on to make the protein it encodes, advancing efforts to use gene and cell-based therapies to treat disease.
A team of investigators led by UCSF and the Gladstone Institutes has found a way to map an enzyme’s underlying molecular machinery, revealing patterns that could allow them to predict how an enzyme behaves – and what happens when this process disrupted.
An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial, UCSF and Yale University report.
UCSF researchers have found a way to knock down cancers caused by a tumor-driving protein called “myc,” paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.
The ability to form blood vessels is one of evolution’s crowning achievements. Now, scientists at the Gladstone Institutes have identified the molecular signals that direct the process of committing endothelial cells to become arteries or veins during embryonic development.
Results of a Phase III clinical trial showed that a simple drug regimen of two anti-clotting drugs lowered the risk of stroke by almost one-third, compared to aspirin alone, when given to patients who had minor or transient stroke symptoms to prevent subsequent attacks.
New research conducted at UCSF sheds lights on how fingers and toes are formed in the womb, a finding likely to fundamentally reshape biologists' understanding of how cells communicate to each other during development.
<p>Five UCSF scientists — bioengineers <a href="http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&Person=4582858">Tejal Desai</a> and <a href="http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&Person=5528568">Shuvo Roy</a>, MD/PhD candidate Mozziyar Etemadi, microbiologist <a href="http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&Person=4733942">Joe DeRisi</a>, and physician/surgeon <a href="http://profiles.ucsf.edu/ProfileDetails.aspx?From=SE&Person=4915217">Michael Harrison</a> — trace their path toward five inventions that are changing the face of medicine in a story featured in the new UCSF Magazine.</p>
<p>Researchers at UCSF have identified the lynchpin that activates brown fat cells, which burn fat molecules instead of storing them, making them the focus of pharmaceutical research aimed at fighting obesity.</p>
<p>UCSF and its affiliates have been major players in the transformation of San Francisco as a leading center of innovation in health care and biosciences, according to a new report released Wednesday.</p>
People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.
A new approach to drug design, pioneered by a group of researchers at UCSF and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.